Table 3.
Association of concurrent therapy with the patient’s status as WRN or no WRN
| Medication group | WRN: ΔSC ≥0.3, n=821 (%) |
No WRN: ΔSC <0.3, n=3185 (%) |
P-value |
|---|---|---|---|
| Drugs that affect blood pressure | 555 (68) | 1787 (56) | <0.001 |
| Drugs that may lower glomerular hydrostatic pressure (e.g., ACE inhibitors, angiotensin receptor blockers, β-blockers, diuretics, non-dihydropyridine CCB, clonidine) |
484 (59) | 1653 (52) | 0.002 |
| Drugs that may raise glomerular hydrostatic pressure (e.g., dihydropyridine CCB, direct-acting smooth muscle relaxants (hydralazine), potassium channel agonists (minoxidil), β-2-adrenergic receptor agonist (albuterol), erythropoietin, endothelin receptor antagonist (bosentan), dobutamine) |
311 (38) | 780 (24) | <0.001 |
| Antilipemic drugs | 167 (20) | 550 (17) | 0.243 |
| Statins | 145 (18) | 473 (15) | 0.243 |
| All other classes of antilipemic drugs | 32 (4) | 125 (4) | 0.972 |
| Drugs that affect the coagulation system | 513 (62) | 1882 (59) | 0.307 |
| Aspirin | 287 (35) | 897 (28) | 0.001 |
| Non-steroidal anti-inflammatory drugs | 36 (4) | 153 (5) | 0.307 |
| Clopidogrel, ticlopidine | 63 (8) | 214 (7) | 0.307 |
| Heparin | 387 (47) | 1627 (51) | 0.001 |
Abbreviations: ACE, angiotensin-converting enzyme; CCB, calcium channel blockers; SC, serum creatinine; WRN, warfarin-related nephropathy.